CIBC Private Wealth Group’s iShares US Pharmaceuticals ETF IHE Stock Holding History

CIBC Private Wealth Group’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$3.31K	Buy	+39	New	+$3.11K	﹤0.01%	2707

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CIBC Private Wealth Group's IHE Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in iShares US Pharmaceuticals ETF (IHE) in Q4 2025: 39 shares worth $3.31K. The stake represents ﹤0.01% of the portfolio and ranks #2707 among its holdings.

178 funds tracked by Wall St. Rank hold IHE as of Q4 2025.

CIBC Private Wealth Group held 39 shares of iShares US Pharmaceuticals ETF worth $3.31K as of Q4 2025.
iShares US Pharmaceuticals ETF was a new CIBC Private Wealth Group position in Q4 2025.
iShares US Pharmaceuticals ETF made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2707 holding.
178 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.